Latest Short Selling News

Firetrail Alpha Plus Fund delivered a 19.05% pre-fee return in the year to 30 June 2026, more than tripling the S&P/ASX 200 Accumulation Index’s 6.01% gain. Net assets almost doubled to $42.944 million as the fund added an ASX-listed unit class and expanded its investor base.

Plato Global Alpha Fund delivered a 26.7% net return for the year ended 30 June 2026, beating its global equity benchmark by 11.9 percentage points. Net assets climbed almost sixfold to $4.75 billion, driven by investment gains and substantial new applications, although the fund’s short positions and currency exposures remain material risks.

Regal Asian Investments (ASX:RG8) posted a stellar FY26 with a net profit after tax of $124.8 million, driven by a 52.6% net portfolio return and a 10 cent fully franked final dividend, reflecting strong exposure to Asian semiconductors amid the AI boom.

Atlas Arteria has lodged its fourth supplementary target’s statement, reiterating its rejection of IFM’s $5.10 per security takeover offer, citing undervaluation and highlighting IFM’s capacity to pay more.

Atlas Arteria’s Independent Directors maintain a unanimous rejection of IFM’s $5.10 per security takeover bid, citing undervaluation and insufficient control premium. The company reiterates its 2026 distribution guidance and confirms active asset sale discussions, including Chicago Skyway.

Perennial Investment Management has launched the Ziller Global Fund Active ETF (ASX: ZILR), targeting high-growth global companies led by exceptional founders. The fund aims to deliver absolute returns above the MSCI All Country World Index over a typical five-year horizon.

Fat Prophets Global Contrarian Fund Ltd has reported a robust 56% increase in net profit for the year ended 30 June 2025, driven by strong investment returns and a leveraged global equity portfolio. The company also declared a fully franked special dividend, reflecting confidence in its ongoing performance.

Regal Asian Investments Limited posted a sharp 92% decline in net profit for FY25 amid volatile Asian markets but maintained a fully franked 6 cent dividend and continued its on-market share buy-back program.

Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.

Montaka Global Extension Fund has announced a distribution of 11.10 cents per unit for the half-year ending December 2024, alongside details of its Distribution Reinvestment Plan and tax component estimates.